Forecast

Buy	13
Hold	1
Sell	0

News Go to news feed

SCYNEXIS reports earnings per share of $0.63 despite sharp revenue decline

For the quarter ended 30 June 2026, SCYNEXIS reported earnings of $0.63 per share, after -$1.12 in the prior year. Revenue fell 83.09 percent to $0.2 million (prior year: $1.4 million). » More on finanzen.net
Scynexis announces 1-for-8 reverse stock split, shares fall about 7%

Scynexis approved a 1-for-8 reverse stock split at an extraordinary general meeting, to take effect on May 29, 2026, and to be traded from June 1, 2026 under the existing ticker symbol but with a new CUSIP. The measure aims to regain compliance with the Nasdaq Capital Market minimum bid price requirement. Outstanding shares will fall from about 79.5 million to around 9.9 million; authorized shares will be reduced proportionally and option exercise prices adjusted accordingly. Shareholders will receive a cash payment for fractional shares, and holdings held at custodians will be adjusted automatically. » More on de.investing.com
SCYNEXIS secures about $40 million in private placement

SCYNEXIS has entered into a purchase agreement with institutional and accredited investors for a private placement with gross proceeds of about $40 million at an offering price of $0.92 per unit. The transaction includes 34,750,000 common shares as well as pre-funded warrants and accompanying warrants that, if fully exercised for cash, could raise an additional $52.2 million (exercise price $1.20). The company expects to close around April 1, 2026, names Guggenheim Securities as placement agent and plans to use net proceeds for working capital and general corporate purposes, with cash expected to be sufficient through mid-2029. CEO Dr. David Angulo also purchased shares and warrants; a shareholder meeting to increase authorized shares is planned within 90 days. » More on de.investing.com

Financials

In the last quarter, Scynexis had revenue of 205.91k€ and net profit of 6.48m€

(EUR)	Jun 2026	YoY
Revenue	+205.91k	82,21%
Gross profit	+205.91k	82,21%
Net profit	+6.48m	210,96%
EBITDA	+6.48m	210,96%

Fundamentals

Metric	Value
Market capitalization	+28.01m€
Number of shares	6.29m
52-week high/low	+8,99€ - +3,03€
Dividends	No
Beta	1,1
P/E ratio	−2,82
PEG ratio	+0,01
P/B ratio	+0,92
P/S ratio	+1,70

Company profile

SCYNEXIS, Inc. ist ein Biotechnologieunternehmen, das Produkte zur Behandlung von Pilzinfektionen in den Vereinigten Staaten entwickelt. Es bietet BREXAFEMME (Ibrexafungerp-Tabletten) für die Behandlung der vulvovaginalen Candidose (VVC) an. Das Unternehmen entwickelt seinen führenden Produktkandidaten, Ibrexafungerp, als neuartiges orales und intravenöses Medikament zur Behandlung verschiedener Pilzinfektionen, einschließlich rezidivierender VVC, invasiver Aspergillose, invasiver Candidose und refraktärer invasiver Pilzinfektionen; und ibrexafungerp, das die Phase-3-CANDLE-Studie zur Prävention rezidivierender VVC abgeschlossen hat. Es unterhält Forschungskooperationen mit Merck Sharp & Dohme Corp, Hansoh (Shanghai) Health Technology Co., Ltd, Jiangsu Hansoh Pharmaceutical Group Company Limited und R-Pharm, CJSC zur Entwicklung und Vermarktung von ibrexafungerp. Das Unternehmen war früher als SCYNEXIS Chemistry & Automation, Inc. bekannt und änderte im Juni 2002 seinen Namen in SCYNEXIS, Inc. SCYNEXIS, Inc. wurde 1999 gegründet und hat seinen Hauptsitz in Jersey City, New Jersey.